^
Association details:
| Biomarker: | TP53 amplification |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Talzenna (talazoparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer
Published date:
01/10/2022
Excerpt:
...we also showed that PARPi talazoparib had some disease stabilization activity in CN-high/p53mut EC, which can potentially be enhanced by combination therapies.
DOI:
10.1186/s13073-021-00990-z
